Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
2.040
+0.030 (1.49%)
Nov 17, 2026, 4:00 PM EST - Market closed
← View all transcripts

A.G.P. Virtual Consumer Showcase

Nov 12, 2026

Summary

The presentation outlined a four-part strategy spanning consumer products, ingredients, IV/injections, and rare-disease drug development. Management cited flat supplement sales this year, stepped-up marketing, and continued investment in R&D alongside positive cash flow goals.

Aaron Grey
Analyst, A.G.P.

Welcome to another session of A.G.P.'s Consumer Showcase. Really excited for the next company we have in store, Niagen Bioscience. We have CEO Rob Fried, as well as CFO Ozan Pamir. Ozan, Rob, thanks so much for joining me.

Rob Fried
CEO, Niagen Bioscience

Thanks, Aaron.

Aaron Grey
Analyst, A.G.P.

All right. If you guys have any questions for the Niagen team, go and type those into the Q&A, and we'll try and get those answered during the session or at the end. To kick things off, it'd be great for you to give us an overview of the Niagen Bioscience story, as some of the listeners may be new to the name here.

Rob Fried
CEO, Niagen Bioscience

Niagen Bioscience has been in business about 25 years. Started as a standards testing company, ingredients testing service, pivoted into the ingredient business. One of the ingredients that it patented was called nicotinamide riboside, which is probably the most consequential new ingredient to have emerged in the dietary supplement ingredient industry in the last 30 or 40 years. Nicotinamide riboside, that we call Niagen, is an outstanding precursor to something called NAD, which stands for nicotinamide adenine dinucleotide. There are other ways to elevate NAD, but none are as efficient or as safe or as researched as Niagen. NAD is vital to the health of all living cells, plant and animal. All living cells have NAD in it. All important metabolic functions require NAD to function properly, and the more saturated a cell is with NAD, the better it functions.

The primary functions that we look to are energy metabolism, mitochondrial function. You have more mitochondria when you have lots of NAD. It increases mitochondrial biogenesis and better output per mitochondria. Perhaps more important is cellular resilience, the ability of the cells to repair damage, inflammation, oxidative stress, gene mutations or damage, the presence of virus. When the cell manages those problems, it is all NAD dependent. As we age, cells become increasingly damaged. The diminished ability to repair that damage is ultimately what causes aging, and that is why it has become so popular as an anti-aging phenomenon. It works in that regard. Niagen Bioscience is a company presently that is now focused solely on NAD and healthy aging products. We sell nicotinamide riboside, or Niagen, as a dietary supplement. That is Tru Niagen, and we are gradually expanding that consumer products division. We have recently added a skincare product. We call them NanoCloud.

It is Niagen that you can apply directly to the skin. We also have an IV and an injection business, or a telehealth business, if you will, where you can actually inject or get an IV of pharmaceutical-grade Niagen, either at clinics or at home. We also supply Niagen as an ingredient, food grade or pharmaceutical grade, to other dietary supplement companies. Ultimately, what we have been working on for many, many, many years, and we have made great progress on, is a prodrug version of nicotinamide riboside. We call it NB4168, which works far more efficiently than traditional nicotinamide riboside, which we are developing as a rare disease drug for these orphan diseases where children age extremely rapidly.

It turns out that these diseases, and there are quite a few of them, ataxia telangiectasia is one we are focusing on, but there is also Werner syndrome, citrin deficiency, mitochondrial myopathy, other forms of ataxia, where children age very rapidly, and it turns out in most of these cases, these children have non-detectable levels of NAD. This is a real material example of the relationship between NAD levels and the way the body ages. We sort of all have a form of this disease. As we age and our NAD levels decline, our bodies age. We have made great progress in the orphan disease space of advancing this molecule toward drug approval in that space. That is Niagen Bioscience. It has got several verticals all attacking the nicotinamide riboside Niagen space, but all from different modalities and different approaches.

Aaron Grey
Analyst, A.G.P.

Really appreciate that overview, Rob. We are going to dive into some of those verticals here today. Maybe to kick things off, interest in NAD+ and longevity has grown significantly. Can you talk about the size and growth of the category, and what differentiates Niagen or NR from other NAD+ precursors?

Rob Fried
CEO, Niagen Bioscience

Yeah. I mean, we believe that we are the primary reason the category has taken off as it has. Most companies that sell a dietary supplement maybe will do one or two clinical studies, if you will. To date, we have had 52 peer-reviewed published clinical studies on Niagen and nicotinamide riboside, and there are another 30 presently going on in the clinic. I mean, we are a very, very highly advanced R&D science-based company. I think NAD probably as a dietary supplement market globally is probably in the $3 billion range at this point. When we started this thing 8- 10 years ago, it was maybe a $10 million market. I mean, it has grown precipitously because people are interested in aging better, and the science is very compelling, uniquely compelling, not only from a mechanistic standpoint, but also from a peer-reviewed published study standpoint.

The best way to elevate NAD, the safest way to elevate NAD is with Niagen, with nicotinamide riboside. There are other molecules out there that can elevate NAD, not as safely, not as efficiently, not as well. There are many products that have recently emerged in the marketplace that do not do it at all, but still make that claim. But the best, most efficient, and safest way to do it is with Niagen. I can explain to you exactly scientifically why that is the case, mechanistically why that is the case. The industry itself mostly consists of three main ingredients: nicotinamide riboside, also known as Niagen, also known as NR, which we have patented and control. There is one called NMN, nicotinamide mononucleotide, which does not have a transporter, cannot get into cells.

The reason why NMN does work, however, is because as it circulates through your bloodstream and through your liver and back through your bloodstream, it metamorphosizes and breaks apart into smaller molecules, one of which is actually nicotinamide riboside. NMN is a delivery mechanism for a smaller dose of nicotinamide riboside. That process, though, in the long term, may not be as safe. There is an enzyme called CD38, which is associated with damaged, old, inflamed cells. NMN actually is a substrate for CD38, whereas Niagen actually inhibits CD38. The presence of CD38 may not be obvious in a couple of months, but over the course of a year or two, it may be. Then the third ingredient that I would say is in the NAD space is NAD itself. Oddly, that is actually the largest category of the three. Many people literally take NAD as an ingredient.

This is not a good idea. There are zero studies that show taking NAD actually elevate NAD. There are many studies that show it creates inflammation because it has no way of getting into the cell. Whereas NMN breaks apart and a little bit of NMN turns into NR and does get into the cell, it is not the case with NAD. Many people are actually injecting or getting IVs of NAD. If you know anyone who has done it, they will tell you, "It took me three hours. I had to break out in sweats, and I had chest pains." That is because NAD is not bioavailable.

Niagen, however, if you take through an IV, will just take a few minutes, has very high elevation levels of NAD, and does not have those side effects. So, it is the best molecule. The science is the best around NR or Niagen. The challenge for us as a business is educating the general consumer about those facts.

Aaron Grey
Analyst, A.G.P.

Okay, I really appreciate that. Let's talk about your branded product, Tru Niagen, roughly a $100 million business today. Can you talk about the different sales channels you sell through, including your own website and third-party e-commerce like Amazon, as well as brick-and-mortar retail?

Rob Fried
CEO, Niagen Bioscience

Yeah, the bulk of the Tru Niagen business is Amazon and our website. We also sell it in parts of Asia in a retail chain called Watsons, and we are in limited retail here in the U.S. That is the bulk of the Tru Niagen distribution business. It is about a $100 million dietary supplement, and that makes it, as a single SKU dietary supplement, one of the two or three biggest-selling dietary supplements in the country. Our opportunity is to take that single supplement ingredient and build around it a wider portfolio of dietary supplements and skincare products. As I said before, we also sell Niagen to certain select companies as an ingredient, and they put Niagen in some of their dietary supplements. So, there are certain brands, if it says Niagen, you can trust it.

We sell it to Nestlé, they sell it to our brand and their Pure Encapsulations brand. There is a company called Life Extension, they sell Niagen products. If it says Niagen, you can trust it, and it works. We do supply to certain of our, what you might call conventional competitors.

Aaron Grey
Analyst, A.G.P.

You've talked about expectations for your own website to grow 15%-20%, but total e-commerce closer to 5%. What's the gap in terms of the growth rates of your own site versus other marketplaces like Amazon?

Rob Fried
CEO, Niagen Bioscience

Well, last year we grew a little over 30% year-over-year, and this year we're flat. The reason for that is the presence of all these competitors out there that are selling at a much lower price. We're managing a competitive landscape and a competitive marketplace. But we already see that starting to turn around as people and experts and physicians start to understand that, no, the real thing that you want is Niagen. The real thing that you want is NR. We expect the growth of the dietary supplements to resume, and also as we expand other SKUs and other products into the space. For example, we recently introduced this skincare product that we call NanoCloud.

Of course, before we did that, we did several studies that showed that if you actually apply Niagen to the face directly, it penetrates the skin and actually elevates NAD in skin cells. And one company, Estée Lauder, did their own independent study comparing Niagen to another ingredient called niacinamide, also known as nicotinamide, which is one of the most popular ingredients in the whole skincare space. And Niagen handily beat niacinamide. They and other major skincare companies are now interested in making a deal with us to supply to them Niagen so that they can create skincare products and put out in the market. We expect one of those big companies to have a product in the market widely distributed in the first quarter of next year.

We're expanding our portfolio of consumer products in addition to just the single Tru Niagen SKU in skincare and other dietary supplements. But also, we see that the general public is starting to understand that NAD is important for your health, and the best way to elevate NAD is with Niagen.

Aaron Grey
Analyst, A.G.P.

Mm-hmm. You've talked a bit about the competitive landscape. As you look to market Niagen and the benefits of it, can you talk about marketing spend and consumer acquisition given how competition in NAD has been intensifying?

Rob Fried
CEO, Niagen Bioscience

Right. About a year ago, the administration changed a rule that the FDA had already ruled multiple times. There's this thing called the drug preclusion rule, where if an ingredient is investigated as a drug before it is sold as a supplement, it is never legal to sell as a supplement. One of these competing ingredients called NMN, was being investigated as a drug and was ruled illegal multiple times, and then suddenly last year, the FDA reversed that ruling. Since then, you've seen literally hundreds, thousands of NMN SKUs on the marketplace, and that has created real competition for us. As is always the case, the Wall Street investors dramatically overreacted to it, and our stock dropped considerably because of that. It's reasonable for it to have adjusted because there's now more competition in the marketplace, probably over-adjusted, as tends to happen.

But as a result, we've decided to increase our top-of-the-funnel spend, and we've begun creating more brand awareness-type marketing. We recently launched a campaign with Kelly Slater. Kelly Slater is the greatest historical surfer of all time. He was the youngest to win a competition and the oldest to win a competition. He's 54 and still competing and winning. We consider people who do exceptional things, super agers, if you will, to be the types of influencers that we want to work with, and we're doing that starting with Kelly Slater. For the time being, our relationship between marketing and total revenue, that percentage has gone up and may continue to go up for a quarter or two until it settles back down. By the way, we sued the FDA over that ridiculous decision that we consider reckless.

Not to be sarcastic, but it seems like the current administration wants to legalize virtually everything. That was a reckless call. We think we have a very good chance of reversing that reversal. For any investor that's looking for a "catalyst," that would be a very good one to watch out for, a decision on that. I'd also point out that all of the NMN that's on the market right now that we have looked at is infringing on one of four patents that exist. We have two of the NMN patents. There's another company that has two others. They haven't been enforced yet, but we think eventually they will be enforced, so you'll see NMN come off the market in some way, either through the FDA or that. Our business plan is not assuming that.

We are showing from an education standpoint that Niagen is superior, and we're doing other things as well, which I'm sure you and I will get into shortly. But there is a very good chance that between the patents and the FDA ruling, a reversal of the FDA ruling, you'll see the amount of competition that we're facing in the dietary supplement space to be drastically reduced.

Aaron Grey
Analyst, A.G.P.

Thanks for the overview, Rob, and can certainly appreciate how the competitive dynamics could change given some of the things that you just mentioned right now in terms of whether it be patent or the FDA lawsuit, which we'll touch on maybe more in a bit. But as we go back into marketing and the competitive landscape today, there's a lot of confusion in the marketplace. Consumer can go into a GNC Vitamin Shoppe, go online, they're seeing NR, they're seeing NAD+, they're seeing NMN, they're seeing Niagen. As you're marketing, how do you aim to demonstrate that Niagen is the best method for a consumer as they're seeing all these different options?

Rob Fried
CEO, Niagen Bioscience

The dietary supplement space, like many spaces in healthcare, is fairly trendy. Things get hot, then they cool off, then they get hot again, then they cool off, then they get hot again. NAD really got super hot about one year ago and has actually plateaued a little bit, still growing, but at a slower rate. The reason why we think we're inoculated against that is because of the amount of research and actual published clinical studies we do. We let the science dictate the marketing, not the marketing dictate the science. And there are numerous published studies that show, for example, that there was a study that came out of Norway last year that showed that NR was 2.3x more effective at elevating NAD than NMN. And there are zero studies that show that NAD+ itself elevates NAD.

More and more, the journalists and the podcasters and the investors that research and ultimately the general consumer will realize, as NAD continues to hit the general consciousness, that the scientifically proven best way to elevate NAD is through the molecules we control, nicotinamide riboside. So yeah, we will continue to educate people. We educate doctors, we educate healthcare practitioners, and podcasters, and journalists. But in the final analysis, the data speak for themselves.

Aaron Grey
Analyst, A.G.P.

Okay, great. Appreciate that, Rob. Let's talk about one of the other parts of the business on the ingredient side. Can you discuss Niagen's ingredient business, who your clients are, and your outlook for adding new ingredient partners?

Rob Fried
CEO, Niagen Bioscience

Our primary customers in the Niagen ingredient business are Nestlé, H&H, and Life Extension. We recently announced a deal with a company called Goli that's going to release an actual gummy with Niagen in it shortly, and there are a few others. We're very careful about to whom we license it. There are many companies in the dietary supplement space you've never heard of. They're quick startup companies that make claims. They make a deal with a celebrity or a doctor or something. All of a sudden, they make big, bold claims until they hear from the FDA or the FTC or something happens. We're careful about to whom we supply it. We know we have a magical ingredient here, a great once-in-a-lifetime ingredient. We're careful about to whom we supply it.

The company is so good at innovating and developing new ingredients that we have actually developed a new form of nicotinamide riboside, and that's called nicotinamide riboside malate, which is significantly more effective and safe than NMN, and certainly much more than NAD+, but less than our traditional Tru Niagen. We can make it at a much reduced price. We intend to offer this nicotinamide riboside malate to a wider swath of dietary supplement companies who will probably sell their version of it on the market at a much reduced price, which would be quite competitive with all the other products that are out there on the market. We have yet to decide whether we, Niagen Bioscience, want to create our own Tru Niagen product with this malate form.

In the short run, we will be selling it as an ingredient to a wider range of dietary supplement brands.

Aaron Grey
Analyst, A.G.P.

Okay, right. That salt form is lower cost to compete better with NMN in the marketplace for ingredients.

Rob Fried
CEO, Niagen Bioscience

Correct.

Aaron Grey
Analyst, A.G.P.

Okay, great. Appreciate that color there. Let's touch base a little bit in terms of Niagen Plus telehealth platform and some of your at-home injection kit business. Can you explain Niagen Plus offering, why telehealth is the right channel, and how big you believe that injection at home business can be for you?

Rob Fried
CEO, Niagen Bioscience

The way we see the Niagen Plus business, which is the IV and the injection delivery mechanism for nicotinamide riboside, like everything that we do, we spent many years developing that business. We got on the Category 1 FDA list so that it was legal to compound nicotinamide riboside and offer it through that modality, direct injection. We then conducted numerous studies to show that it was safe to do so and compare it to other products on the space, like NAD. It compares extremely favorably to NAD as an injection product or an IV product. Anyone who is injecting themselves with NAD or IV, stop. Go get Niagen. You're not helping yourself. You're hurting yourself. You think you're helping yourself, but you're not. Niagen will not create the inflammation, will elevate NAD much higher and much faster, and doesn't have any of those side effects.

The next thing we did was make sure that it was pharmaceutical-grade safe version of Niagen. If it's injected or IV, it has to be pharma grade, not food grade, like a dietary supplement. That took a long time for us to develop. Of course, like everything we do, our level of quality assurance is extremely high. It was a very time-consuming space. Then we put together deals with a couple of compound pharmacies and deals with these IV clinics that deliver IVs. We see it mostly as an API business, as selling the ingredient to clinics or telehealth companies like Ro or some of these other companies that sell at-home kits. We developed our own telehealth capability almost as a way of showing the existing telehealth companies or clinics that this can be done.

We don't know if that's a business that we're going to invest in aggressively. It might be. It seems to be selling okay so far. People seem to be buying Niagen at-home kits from us. We don't have a wide assortment of peptides and other molecules that we're selling via at-home kits or at home. Whether we invest in that at this point is undecided.

Aaron Grey
Analyst, A.G.P.

Okay. Great. Appreciate that. I want to make sure we talk about your pharma side of the business as well. You talked about it a little bit in your prepared remarks, but could you expand on that and how that differs from maybe your direct-to-consumer part of the business?

Rob Fried
CEO, Niagen Bioscience

Well, of course, it's a completely different set of regulations and a different commercial system, and it's even a different molecule. NB4168 is not the same molecule as nicotinamide riboside chloride, if you will. It's bio-superior. It has orders of magnitude greater amounts of delivery of NR into the bloodstream than does Tru Niagen. We've already actually conducted and published two phase II clinical studies on Tru Niagen for ataxia telangiectasia, and the results were extremely positive. The reason we pivoted away from Niagen as a drug candidate to NB4168 is, well, number one, it's superior. Number two, the pharmaceutical companies with whom we will ultimately partner and the insurance companies would prefer to see that it is a differentiated and superior molecule than the one that's already being sold as a dietary supplement. There are safe health reasons and commercial reasons why. The rare disease space lately has gotten quite interesting.

The vouchers that are given biotech companies that get drug approval for rare diseases have gone up to over $200 million per voucher in the resale market. The price per patient per year of rare disease, orphan disease drugs has gone into the upper hundreds of thousands of dollars per year. So the economics have become quite compelling, and Congress is now introducing legislation to reduce the time and cost to getting rare disease approval by 30%. So rare diseases in general have become extremely interesting, and we've been aggressive about this now for almost 10 years working on this thing. There are biotech companies out there pursuing rare diseases just like ataxia.

In fact, one is actually pursuing ataxia, that do not have a cash flow positive $100 million business, that are losing $10 million per quarter while they pursue drug approval, and as of today, have double the market cap as do we. With us, you get the upside, and it is massive upside for a drug business, a biotech drug pursuit business. But at the same time, you have a well-managed cash flow positive diversified consumer business that has molecules that it actually controls with a moat around the drugs. That is the way we see it. We see this business as a cash-generating business with a very healthy balance sheet, a very interesting business plan, outstanding technology and science, and a very competent management team that is already proven its ability to execute, that has the downside risk covered, yet the upside potential of this pharmaceutical-grade rare disease opportunity.

Aaron Grey
Analyst, A.G.P.

Okay. Appreciate that, Rob. Let us talk about financials a bit. Gross margin, 63% in 3Q. EBITDA was positive $500,000, down from $6.4 million prior. Maybe just tell us a bit about how we should think about balancing and investing for long-term growth versus near-term profitability and how that relates to both the gross margin and EBITDA margin.

Rob Fried
CEO, Niagen Bioscience

Yeah, it is like what I was saying to you just now. Obviously, we have to be sensitive to the stock price somewhat. There is maybe $20 million, maybe even as much as $30 million out there in the float that gets traded, and people seem to react very dramatically to quarterly earnings or news or some development. If you look over the last few years, the stock has been extraordinarily volatile, exceptionally volatile. But it is not how we look at it. The business plan that I just described to you with the four segments, the Consumer business, the Ingredient business, the Niagen Plus business, and the biotech, the Pharma business, these have been in place for seven or eight years now, and we gradually pursue all of them.

Our goal is to show profitable growth, to be cash flow positive, at the same time investing very aggressively in R&D to develop out these other businesses that all have enormous upside potential. If that is your overall overarching thesis of the way you operate, it does not completely jibe with the idea of really just thinking quarter to quarter to quarter. It is not that we are insensitive to it. We are sensitive to it, but we are more thinking long term. We think the stock has tens of billions of dollars of upside potential. NAD itself is an immeasurably large market potential. Just imagine, if you safely elevate NAD, every damaged cell in your body becomes more resilient and metabolizes more energy. In essence, makes it a younger, more youthful, more resilient cell.

How big is the market cap, the market potential for an ingredient that does that safely and brought to you by some of the best researchers in the world, Nobel Prize-winning researchers who are doing this work with us? That's a very, very large potential, very big upside. We focus on all the modalities, topical, IV, injection, drug, and dietary supplement, because we think the market potential is that big. If you're thinking that big, you're not necessarily thinking weeks or months. You're more thinking months or years.

Aaron Grey
Analyst, A.G.P.

Okay. Great. Appreciate that, Rob. Just last one quickly here, just for the Consumer Showcase. How are you thinking about the state of the consumer today? As we head into 2027, how do you think Niagen's best positioned for where the consumer is and heading to?

Rob Fried
CEO, Niagen Bioscience

Well, obviously, there's much more focus on longevity in general. We're positioned nicely in that overarching category. Awareness of NAD is continuing to accelerate, not just in the U.S., but globally. People are aware that there are many products claiming to elevate NAD or even to improve longevity, so we have an education challenge. What we're also noticing in consumers is increasing scientific knowledge. Maybe this is part of the LLM contribution, ChatGPT and Claude, helping people to become more informed and smarter about what they're taking, how they're taking it, what works, what doesn't work, what science is behind it. We see all of that as working to our advantage because we are so genuinely science-based. It's not just words for us. Companies that we compete with don't do what we do in terms of research and studies and proprietary molecules.

We think we're swimming downstream in terms of where the consumer is positioned right now.

Aaron Grey
Analyst, A.G.P.

Okay, fantastic. I think that's a great way for us to end things. Rob, Ozan, thanks so much for joining me here today. Again, Niagen Bioscience, traded on the NASDAQ, ticker NAGE. Rob, Ozan, thanks again.

Rob Fried
CEO, Niagen Bioscience

Thank you.

Aaron Grey
Analyst, A.G.P.

Thank you, and thank you everyone for joining us.